Serological screening and metabolic analysis for evaluation of the immune response to SARS-CoV2 (COVID-19)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022292

Enrollment

250

Registered

2020-06-26

Start date

2020-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Group 1: subjects exposed to SARS-CoV2 (contact with SARS-CoV2-infected people) Group 2: historic controls (biomaterial from 2019 or earlier available)

Eligibility

Sex/Gender

All

Age

5 Years to No maximum

Inclusion criteria

Inclusion criteria: Age at least 5 years, signed written informed consent form (for <18 years old, signed by the parent)

Exclusion criteria

Exclusion criteria: acute symptoms of COVID-19 in the last two weeks (fever, cough, shortness of breath)

Design outcomes

Primary

Measure	Time frame
The primary outcome is the level of IgM- and IgG antibodies against SARS-CoV2. The titers will be measured up to 3x within one year. In one part of the experiments we will also study the virus-specific Tcells.	—

Secondary

Measure	Time frame
The prevalence of antibodies in the population, a correlation between antibody titer, virus-specific T cells and symptoms; the correlation between metabolic parameters in immune cells, antibody titers and symptoms.	—

Countries

Germany

Contacts

Public ContactCornelius Waller

Universitätsklinikum Freiburg Klinik für Innere Medizin I

cornelius.waller@uniklinik-freiburg.de+49 (0)761 270 34220

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026